发布时间：2008.10

摘要

Countries covered: Global

The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology.

In his report HIV Markets for Diagnostics and Therapeutics, anlayst Kenneth Krul, PhD examines these focal points, with an eye to creating a comprehensive look at the market and opportunity for both testing and treatments of HIV. Dr. Krul takes a look at the potential theoretical markets and what will be realistic in the current world healthcare system.

The report contains extensive epidemological statistics for HIV in the following WHO health regiions:

• Sub-Saharan Africa
• Middle East and North Africa
• South and South-East Asia
• East Asia
• Latin America
• Caribbean
• Eastern Europe and Central Asia
• Western and Central Europe
• North America
• Oceania

In addition the report contains:

• Current Market Sizes for HIV Treatments and Diagnostics in each WHO Health Region (treatment and diagnostic markets)
• Profiles of Companies in this Market
• Eleven Important Conclusions
• Review of Current Treatment Products and Diagnostic Tools.

As with all Kalorama Information reports, this product is the result of primary and secondary research. Interviews with experts, as well as research into company reports, medical literature and government data is included.

目录及图表

CHAPTER ONE: EXECUTIVE SUMMARY

• Potential and Realistic Markets
• Figure 1-1: “Theoretical” Distribution of HIV Market
• Figure 1-2 Realistic Market for HIV/AIDs Diagnostics
• Table 1-1: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008
• Table 1-3: Regional HIV/AIDS Statistics: 2001 and 2007
• Technology
• Key HIV/AIDS Market Issues
• Scope and Methodology

CHAPTER TWO: INTRODUCTION AND EPIDEMIOLOGY

• HIV/AIDS Complications
• HIV/AIDS Epidemiology
• Table 2-1: Global Summary of HIV/AIDS Populations: 2007 (Category, Average, Range)
• Figure 2-1: Estimated People Living With HIV/AIDS Globally: 1990 - 2007
• Figure 2-2: Estimated Number of Adult and Child Deaths Due to AIDS Globally: 1990 - 2007
• Figure 2-3: Estimated Incidence of HIV Infection Globally: 1990 - 2007 Sub-Saharan Africa
• Table 2-2: Regional HIV/AIDS Statistics (I): 2001 and 2007 (Millions)
• Table 2-3: Regional HIV/AIDS Statistics (II): 2001 and 2007
• Figure 2-4: Estimated HIV Prevalence Rates (%) in Adults (15 - 49 Years) Globally and in Sub-Saharan Africa: 1990 - 2007
• Table 2-4: Adult (Aged 14 - 49 years) HIV Prevalence in Sub-Saharan Countries That Have Recently Conducted Population-Based HIC Studies
• Table 2-4 (continued): Adult (Aged 14 - 49 years) HIV Prevalence in Sub- Saharan Countries That Have Recently Conducted Population-Based HIC Studies
• Asia
• Eastern Europe and Central Asia
• The Caribbean
• Latin America
• North America, Western and Central Europe
• Figure 2-5: AIDS Distribution by Race in the United States: 2006
• Figure 2-6: Risk Factors Associated with AIDS in Men in the United States: 2006
• Table 2-5: Prevalence of HIV Infection in the United States Based on Sample Testing: 2006
• Figure 2-5: AIDS Distribution by Race in the United States: 2006
• Figure 2-6: Risk Factors Associated with AIDS in Men in the United States: 2006
• Figure 2-7: Risk Factors Associated with AIDS in Women in the United States: 2006
• The Middle East and North Africa

CHAPTER THREE: HIV/AIDS SCREENING AND DIAGNOSIS

• Level 1: Screening
• Level 2: Confirmatory Testing
• Level 3: Diagnosis
• Table 3-1: HIV Screening and Confirmatory Testing Products Approved for Use in the United States as of July 9, 2008
• Table 3-2: Conditions Attributable to or Complicated by HIV
• Table 3-3: AIDS Indicator Conditions
• Level 4: Monitoring Treatment and Prognosis

CHAPTER FOUR: HIV/AIDS THERAPEUTICS

• Drug Therapy
• Figure 4-1: Binding of HIV to T-Cells
• Table 4-1: HIV Entry/Fusion Inhibitors; FDA-Approved and in Development: 2008
• Table 4-2: Nucleoside Reverse Transcription Inhibitors (NRTI); FDA-Approved and in Development: 2008
• Table 4-3: Non-Nucleoside Reverse Transcription Inhibitors (NNRTI); FDA-Approved and in Development: 2008
• Figure 4-3: HIV Integration
• Table 4-4: Integrase Inhibitors; FDA-Approved and in Development: 2008
• Figure 4-4: HIV Transcription
• Figure 4-5: HIV Translation
• Figure 4-6: HIV Assembly and Maturation
• Table 4-5: Protease Inhibitors (PI)/Maturation Inhibitors (MI); FDA-Approved and in Development: 2008
• Pediatric HIV/AIDS
• Table 4-6: Anti-HIV Drugs in Development: 2008
• Table 4-7: Anti-HIV Drugs Approved for Pediatric Use
• Chemokine Therapeutics and HIV
• Genes and HIV/AIDS
• HIV/AIDS Vaccines

CHAPTER FIVE: MARKET ANALYSIS

• Table 5-1: Estimated Theoretical Potential for HIV/AIDS Diagnostics and Therapeutics: 2008
• Figure 5-1 HIV/AIDS Market by Major World Regions
• Table 5-2: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008 Technology Key HIV/AIDS Market Issues

CHAPTER SIX: COMPANY SNAPSHOTS

• Abbott Laboratories
• Abbott Molecular Diagnostics
• Bristol-Myers Squibb
• Calypte Biomedical Corp.
• Celera Diagnostics
• Gen-Probe Incorporated
• Gilead Sciences
• GlaxoSmithKline plc
• Luminex Corporation
• QIAGEN GmbH
• Roche Molecular Systems
• Tibotec, Inc. (A Johnson & Johnson Company)
• VIRxSYS Corporation

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

• First Conclusion
• Second Conclusion
• Third Conclusion
• Fourth Conclusion
• Fifth Conclusion
• Sixth Conclusion
• Seventh Conclusion
• Eighth Conclusion
• Ninth Conclusion
• Tenth Conclusion
• Eleventh Conclusion

CHAPTER EIGHT: GLOSSARY